{"id":11949,"date":"2025-10-10T11:57:43","date_gmt":"2025-10-10T04:57:43","guid":{"rendered":"https:\/\/nhathuocngocanh.com\/bp\/?p=11949"},"modified":"2025-10-10T11:57:43","modified_gmt":"2025-10-10T04:57:43","slug":"desmopressin","status":"publish","type":"post","link":"https:\/\/nhathuocngocanh.com\/bp\/desmopressin\/","title":{"rendered":"Desmopressin"},"content":{"rendered":"

(Ph. Eur. monograph 0712)<\/p>\n

C_{46<\/sub>H_{64<\/sub>N_{14<\/sub>O_{12<\/sub>S_{2<\/sub> 1069 16679-58-6<\/p>\n}}}}}

Action and use<\/strong><\/p>\n

Vasopressin analogue; treatment of diabetes insipidus; nocturnal enuresis; haemophilia; von Willebrand\u2019s disease.<\/p>\n

Preparations<\/strong><\/p>\n

Desmopressin Injection<\/p>\n

Desmopressin Intranasal Solution<\/p>\n

Desmopressin Nasal Spray<\/p>\n

Desmopressin Oral Lyophilisate<\/p>\n

Desmopressin Tablets<\/p>\n

DEFINITION<\/h2>\n
(3-Sulfanylpropanoyl)-L-tyrosyl-L-phenylalanyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-D-arginylglycinamide cyclic (1\u21926)-disulfide.<\/p>\n
Synthetic cyclic nonapeptide, available as an acetate.<\/p>\n
Content<\/h3>\n
95.0 per cent to 105.0 per cent (anhydrous and acetic acid-free substance).<\/p>\n
CHARACTERS<\/h2>\n
Appearance<\/h3>\n
White or almost white, fluffy powder.<\/p>\n
Solubility<\/h3>\n
Soluble in water, in ethanol (96 per cent) and in glacial acetic acid.<\/p>\n
IDENTIFICATION<\/h2>\n
A. Examine the chromatograms obtained in the assay.<\/p>\n
Results: The retention time and size of the principal peak in the chromatogram obtained with the test solution are approximately the same as those of the principal peak in the chromatogram obtained with the reference solution.<\/p>\n
B. Amino acid analysis (2.2.56). For hydrolysis use Method 1 and for analysis use Method 1.<\/p>\n
Express the content of each amino acid in moles. Calculate the relative proportions of the amino acids, taking 1\/6 of the sum of the number of moles of aspartic acid, glutamic acid, proline, glycine, arginine and phenylalanine as equal to 1. The values fall within the following limits: aspartic acid: 0.90 to 1.10; glutamic acid: 0.90 to 1.10; proline: 0.90 to 1.10; glycine: 0.90 to 1.10; arginine: 0.90 to 1.10; phenylalanine: 0.90 to 1.10; tyrosine: 0.70 to 1.05; half-cystine: 0.30 to 1.05. Lysine, isoleucine and leucine are absent; not more than traces of other amino acids are present.<\/p>\n
TESTS<\/h2>\n
Specific optical rotation (2.2.7)<\/h3>\n
-72 to -82 (anhydrous and acetic acid-free substance).<\/p>\n
Dissolve 10.0 mg in a 1 per cent V\/V solution of glacial acetic acid R and dilute to 5.0 mL with the same acid.<\/p>\n
Related substances<\/h3>\n
Liquid chromatography (2.2.29): use the normalisation procedure.<\/p>\n
Test solution: Dissolve 1.0 mg of the substance to be examined in 2.0 mL of water R.<\/p>\n
Resolution solution: Dissolve the contents of a vial of oxytocin\/desmopressin validation mixture CRS in 500 \u03bcL of water R.<\/p>\n
Column:<\/p>\n
\u2014 size: l = 0.12 m, \u00d8 = 4.0 mm;<\/p>\n
\u2014 stationary phase: octadecylsilyl silica gel for chromatography R (5 \u03bcm).<\/p>\n
Mobile phase:<\/p>\n
\u2014 mobile phase A: 0.067 M phosphate buffer solution pH 7.0 R; filter and degas;<\/p>\n
\u2014 mobile phase B: acetonitrile for chromatography R, mobile phase A (50:50 V\/V); filter and degas.<\/p>\n\n\n\n\n\n\n\n\n
Time<\/strong><\/p>\n
(min)<\/strong><\/td>\n
Mobile phase A<\/strong><\/p>\n
(per cent V\/V)<\/strong><\/td>\n
Mobile phase B<\/strong><\/p>\n
(per cent V\/V)<\/strong><\/td>\n<\/tr>\n
0 – 4<\/td>\n 76<\/td>\n 24<\/td>\n<\/tr>\n
4 – 18<\/td>\n 76 \u2192 58<\/td>\n 24 \u2192 42<\/td>\n<\/tr>\n
18 – 35<\/td>\n 58 \u2192 48<\/td>\n 42 \u2192 52<\/td>\n<\/tr>\n
35 – 40<\/td>\n 48 \u2192 76<\/td>\n 52 \u2192 24<\/td>\n<\/tr>\n
40 – 50<\/td>\n 76<\/td>\n 24<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
Injection: 50 \u03bcL.<\/p>\n
Retention time: Desmopressin = about 16 min; oxytocin = about 17 min.<\/p>\n
System suitability: Resolution solution:<\/p>\n
\u2014 resolution: minimum 1.5 between the peaks due to desmopressin and oxytoxin.<\/p>\n
Limits:<\/p>\n
\u2014 unspecified impurities: for each impurity, maximum 0.5 per cent;<\/p>\n
\u2014 total: maximum 1.5 per cent;<\/p>\n
\u2014 disregard limit: 0.05 per cent.<\/p>\n
Acetic acid (2.5.34)<\/h3>\n
3.0 per cent to 8.0 per cent.<\/p>\n
Test solution: Dissolve 20.0 mg of the substance to be examined in a mixture of 5 volumes of mobile phase B and 95 volumes of mobile phase A and dilute to 10.0 mL with the same mixture of mobile phases.<\/p>\n
Water (2.5.32)<\/h3>\n
Maximum 6.0 per cent, determined on 20.0 mg.<\/p>\n
Bacterial endotoxins (2.6.14)<\/h3>\n
Less than 500 IU\/mg, if intended for use in the manufacture of parenteral preparations without a further appropriate procedure for the removal of bacterial endotoxins.<\/p>\n
ASSAY<\/h2>\n
Liquid chromatography (2.2.29) as described in the test for related substances with the following modifications.<\/p>\n
Reference solution: Dissolve the contents of a vial of desmopressin CRS in water R to obtain a concentration of 0.5 mg\/mL.<\/p>\n
Mobile phase: Mobile phase B, mobile phase A (40:60 V\/V).<\/p>\n
Flow rate: 2.0 mL\/min.<\/p>\n
Retention time: Desmopressin = about 5 min.<\/p>\n
Calculate the content of desmopressin (C_{46<\/sub>H_{64<\/sub>N_{14<\/sub>O_{12<\/sub>S_{2<\/sub>) from the declared content of C_{46<\/sub>H_{64<\/sub>N_{14<\/sub>O_{12<\/sub>S_{2<\/sub> in desmopressin CRS.<\/p>\n}}}}}}}}}}
STORAGE<\/h2>\n
In an airtight container, protected from light, at a temperature of 2 \u00b0C to 8 \u00b0C. If the substance is sterile, store in a sterile, airtight, tamper-evident container.<\/p>\n
LABELLING<\/h2>\n
The label states:<\/p>\n
\u2014 the mass of peptide per container;<\/p>\n
\u2014 where applicable, that the substance is suitable for use in the manufacture of parenteral preparations.<\/p>\n
IMPURITIES<\/h2>\n
Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other\/unspecified impurities and\/or by the general monograph Substances for pharmaceutical use (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. Control of impurities in substances for pharmaceutical use) A, B, C, D, E, F, G.<\/p>\n
$\"Desmopressin\"$ <\/p>\n
A. [5-L-aspartic acid]desmopressin,<\/p>\n
$\"Desmopressin\"$ <\/p>\n
B. [4-L-glutamic acid]desmopressin,<\/p>\n
$\"Desmopressin\"$ <\/p>\n
C. [9-glycine]desmopressin,<\/p>\n
$\"Desmopressin\"$ <\/p>\n
D. [8-L-arginine]desmopressin,<\/p>\n
$\"Desmopressin\"$ <\/p>\n
E. N -[(acetylamino)methyl]desmopressin,<\/p>\n
$\"Desmopressin\"$ <\/p>\n
F. N -[(acetylamino)methyl]desmopressin,<\/p>\n
$\"Desmopressin\"$ <\/p>\n
G. N ,N -dimethyldesmopressin.<\/p>\n","protected":false},"excerpt":{"rendered":"
(Ph. Eur. monograph 0712) C46H64N14O12S2 1069 16679-58-6 Action and use Vasopressin analogue; treatment of diabetes insipidus; nocturnal enuresis; haemophilia; von Willebrand\u2019s disease. Preparations Desmopressin Injection Desmopressin Intranasal Solution Desmopressin Nasal Spray Desmopressin Oral Lyophilisate Desmopressin Tablets DEFINITION (3-Sulfanylpropanoyl)-L-tyrosyl-L-phenylalanyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-D-arginylglycinamide cyclic (1\u21926)-disulfide. Synthetic cyclic nonapeptide, available as an acetate. Content 95.0 per cent to 105.0 per cent…<\/p>\n","protected":false},"author":4,"featured_media":11978,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[174],"tags":[],"class_list":["post-11949","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicinal-substances"],"acf":[],"_links":{"self":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/11949","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/comments?post=11949"}],"version-history":[{"count":2,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/11949\/revisions"}],"predecessor-version":[{"id":11993,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/11949\/revisions\/11993"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media\/11978"}],"wp:attachment":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media?parent=11949"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/categories?post=11949"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/tags?post=11949"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}

Time<\/strong><\/p>\n (min)<\/strong><\/td>\n	Mobile phase A<\/strong><\/p>\n (per cent V\/V)<\/strong><\/td>\n	Mobile phase B<\/strong><\/p>\n (per cent V\/V)<\/strong><\/td>\n<\/tr>\n
0 – 4<\/td>\n	76<\/td>\n	24<\/td>\n<\/tr>\n
4 – 18<\/td>\n	76 \u2192 58<\/td>\n	24 \u2192 42<\/td>\n<\/tr>\n
18 – 35<\/td>\n	58 \u2192 48<\/td>\n	42 \u2192 52<\/td>\n<\/tr>\n
35 – 40<\/td>\n	48 \u2192 76<\/td>\n	52 \u2192 24<\/td>\n<\/tr>\n
40 – 50<\/td>\n	76<\/td>\n	24<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n Injection: 50 \u03bcL.<\/p>\n Retention time: Desmopressin = about 16 min; oxytocin = about 17 min.<\/p>\n System suitability: Resolution solution:<\/p>\n \u2014 resolution: minimum 1.5 between the peaks due to desmopressin and oxytoxin.<\/p>\n Limits:<\/p>\n \u2014 unspecified impurities: for each impurity, maximum 0.5 per cent;<\/p>\n \u2014 total: maximum 1.5 per cent;<\/p>\n \u2014 disregard limit: 0.05 per cent.<\/p>\n Acetic acid (2.5.34)<\/h3>\n 3.0 per cent to 8.0 per cent.<\/p>\n Test solution: Dissolve 20.0 mg of the substance to be examined in a mixture of 5 volumes of mobile phase B and 95 volumes of mobile phase A and dilute to 10.0 mL with the same mixture of mobile phases.<\/p>\n Water (2.5.32)<\/h3>\n Maximum 6.0 per cent, determined on 20.0 mg.<\/p>\n Bacterial endotoxins (2.6.14)<\/h3>\n Less than 500 IU\/mg, if intended for use in the manufacture of parenteral preparations without a further appropriate procedure for the removal of bacterial endotoxins.<\/p>\n ASSAY<\/h2>\n Liquid chromatography (2.2.29) as described in the test for related substances with the following modifications.<\/p>\n Reference solution: Dissolve the contents of a vial of desmopressin CRS in water R to obtain a concentration of 0.5 mg\/mL.<\/p>\n Mobile phase: Mobile phase B, mobile phase A (40:60 V\/V).<\/p>\n Flow rate: 2.0 mL\/min.<\/p>\n Retention time: Desmopressin = about 5 min.<\/p>\n Calculate the content of desmopressin (C_{46<\/sub>H_{64<\/sub>N_{14<\/sub>O_{12<\/sub>S_{2<\/sub>) from the declared content of C_{46<\/sub>H_{64<\/sub>N_{14<\/sub>O_{12<\/sub>S_{2<\/sub> in desmopressin CRS.<\/p>\n}}}}}}}}}} STORAGE<\/h2>\n In an airtight container, protected from light, at a temperature of 2 \u00b0C to 8 \u00b0C. If the substance is sterile, store in a sterile, airtight, tamper-evident container.<\/p>\n LABELLING<\/h2>\n The label states:<\/p>\n \u2014 the mass of peptide per container;<\/p>\n \u2014 where applicable, that the substance is suitable for use in the manufacture of parenteral preparations.<\/p>\n IMPURITIES<\/h2>\n Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other\/unspecified impurities and\/or by the general monograph Substances for pharmaceutical use (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. Control of impurities in substances for pharmaceutical use) A, B, C, D, E, F, G.<\/p>\n $\"Desmopressin\"$ <\/p>\n A. [5-L-aspartic acid]desmopressin,<\/p>\n $\"Desmopressin\"$ <\/p>\n B. [4-L-glutamic acid]desmopressin,<\/p>\n $\"Desmopressin\"$ <\/p>\n C. [9-glycine]desmopressin,<\/p>\n $\"Desmopressin\"$ <\/p>\n D. [8-L-arginine]desmopressin,<\/p>\n $\"Desmopressin\"$ <\/p>\n E. N -[(acetylamino)methyl]desmopressin,<\/p>\n $\"Desmopressin\"$ <\/p>\n F. N -[(acetylamino)methyl]desmopressin,<\/p>\n $\"Desmopressin\"$ <\/p>\n G. N ,N -dimethyldesmopressin.<\/p>\n","protected":false},"excerpt":{"rendered":" (Ph. Eur. monograph 0712) C46H64N14O12S2 1069 16679-58-6 Action and use Vasopressin analogue; treatment of diabetes insipidus; nocturnal enuresis; haemophilia; von Willebrand\u2019s disease. Preparations Desmopressin Injection Desmopressin Intranasal Solution Desmopressin Nasal Spray Desmopressin Oral Lyophilisate Desmopressin Tablets DEFINITION (3-Sulfanylpropanoyl)-L-tyrosyl-L-phenylalanyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-D-arginylglycinamide cyclic (1\u21926)-disulfide. Synthetic cyclic nonapeptide, available as an acetate. Content 95.0 per cent to 105.0 per cent…<\/p>\n","protected":false},"author":4,"featured_media":11978,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[174],"tags":[],"class_list":["post-11949","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicinal-substances"],"acf":[],"_links":{"self":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/11949","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/comments?post=11949"}],"version-history":[{"count":2,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/11949\/revisions"}],"predecessor-version":[{"id":11993,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/11949\/revisions\/11993"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media\/11978"}],"wp:attachment":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media?parent=11949"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/categories?post=11949"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/tags?post=11949"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}

Content<\/h3>\n95.0 per cent to 105.0 per cent (anhydrous and acetic acid-free substance).<\/p>\n

CHARACTERS<\/h2>\n

Appearance<\/h3>\nWhite or almost white, fluffy powder.<\/p>\n

Solubility<\/h3>\nSoluble in water, in ethanol (96 per cent) and in glacial acetic acid.<\/p>\n

TESTS<\/h2>\n

Specific optical rotation (2.2.7)<\/h3>\n-72 to -82 (anhydrous and acetic acid-free substance).<\/p>\nDissolve 10.0 mg in a 1 per cent V\/V solution of glacial acetic acid R and dilute to 5.0 mL with the same acid.<\/p>\n

Acetic acid (2.5.34)<\/h3>\n3.0 per cent to 8.0 per cent.<\/p>\nTest solution: Dissolve 20.0 mg of the substance to be examined in a mixture of 5 volumes of mobile phase B and 95 volumes of mobile phase A and dilute to 10.0 mL with the same mixture of mobile phases.<\/p>\n

Water (2.5.32)<\/h3>\nMaximum 6.0 per cent, determined on 20.0 mg.<\/p>\n

Bacterial endotoxins (2.6.14)<\/h3>\nLess than 500 IU\/mg, if intended for use in the manufacture of parenteral preparations without a further appropriate procedure for the removal of bacterial endotoxins.<\/p>\n

STORAGE<\/h2>\nIn an airtight container, protected from light, at a temperature of 2 \u00b0C to 8 \u00b0C. If the substance is sterile, store in a sterile, airtight, tamper-evident container.<\/p>\n

LABELLING<\/h2>\nThe label states:<\/p>\n\u2014 the mass of peptide per container;<\/p>\n\u2014 where applicable, that the substance is suitable for use in the manufacture of parenteral preparations.<\/p>\n

Content<\/h3>\n
95.0 per cent to 105.0 per cent (anhydrous and acetic acid-free substance).<\/p>\n

Appearance<\/h3>\n
White or almost white, fluffy powder.<\/p>\n

Solubility<\/h3>\n
Soluble in water, in ethanol (96 per cent) and in glacial acetic acid.<\/p>\n

Specific optical rotation (2.2.7)<\/h3>\n
-72 to -82 (anhydrous and acetic acid-free substance).<\/p>\n
Dissolve 10.0 mg in a 1 per cent V\/V solution of glacial acetic acid R and dilute to 5.0 mL with the same acid.<\/p>\n

Acetic acid (2.5.34)<\/h3>\n
3.0 per cent to 8.0 per cent.<\/p>\n
Test solution: Dissolve 20.0 mg of the substance to be examined in a mixture of 5 volumes of mobile phase B and 95 volumes of mobile phase A and dilute to 10.0 mL with the same mixture of mobile phases.<\/p>\n

Water (2.5.32)<\/h3>\n
Maximum 6.0 per cent, determined on 20.0 mg.<\/p>\n

Bacterial endotoxins (2.6.14)<\/h3>\n
Less than 500 IU\/mg, if intended for use in the manufacture of parenteral preparations without a further appropriate procedure for the removal of bacterial endotoxins.<\/p>\n

STORAGE<\/h2>\n
In an airtight container, protected from light, at a temperature of 2 \u00b0C to 8 \u00b0C. If the substance is sterile, store in a sterile, airtight, tamper-evident container.<\/p>\n

LABELLING<\/h2>\n
The label states:<\/p>\n
\u2014 the mass of peptide per container;<\/p>\n
\u2014 where applicable, that the substance is suitable for use in the manufacture of parenteral preparations.<\/p>\n